atrial fibrillation
NICE set to reject Xarelto in AF
January 10, 2012Sales and Marketing AF, NICE, Pradaxa, Xarelto, atrial fibrillation
NICE says it needs more data on Bayer’s Xarelto in order to recommend it for people with atrial fibrillation. The …
FDA recommends Xarelto for new approval
September 12, 2011Sales and Marketing Xarelto, atrial fibrillation, stroke
FDA advisors have recommended Bayer and Johnson & Johnson’s Xarelto be approved in the US for the prevention of stroke …
Pradaxa approved for stroke prevention in Europe
August 9, 2011Sales and Marketing Pradaxa, atrial fibrillation, direct thrombin inhibitor
Boehringer Ingelheim’s Pradaxa has become the first drug in 50 years to be approved in Europe for stroke prevention in …
Pfizer and BMS to give Eliquis a rolling launch in Europe
May 24, 2011Sales and Marketing Eliquis, Pfizer, apixaban, atrial fibrillation
Pfizer and Bristol-Myers Squibb are gearing up to give their new oral anticoagulant Eliquis a rolling launch in Europe, starting …
Companies join forces to promote AF awareness
February 16, 2011Medical Communications, Sales and Marketing AF, Multaq, Pradaxa, apixaban, atrial fibrillation
Boehringer Ingelheim and Sanofi-Aventis are to co-sponsor the World Heart Federation’s global atrial fibrillation (AF) education campaign. AF AWARE was …
Bayer submits new Xarelto indications for European approval
January 6, 2011Sales and Marketing Bayer, DVT, Xarelto, atrial fibrillation, deep vein thrombosis, pulmonary embolism, rivaroxaban, stroke prevention
Bayer is seeking European regulatory approval for a batch of new indications for its oral anticoagulant Xarelto. The company is …
Latest content
Five Facts about cardiovascular disease
